In this line, the expression of the estrogen receptor (ER), progesterone receptor (PR), and HER2 biomarkers are related to a better prognosis and response to therapy in breast cancer patients than those with the absence of these biomarkers [135]. Here, ERBB2 is linked to breast carcinoma.